Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
NCT03739112
Completed
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older. One dose of VLP Influenza Vaccine (30 μg/strain) or of Comparator (15 μg/strain) was to be administered to 12,738 participants.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/29/2023
Locations: (Site 206) Benchmark Research, Austin, Texas +5 locations
Conditions: Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
Register for Updates
Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children.
NCT01964989
Completed
Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children ≥6 to \<72 Months of Age. The study was conducted during the 2013/2014 and 2014/2015 northern hemisphere influenza season.
Gender:
ALL
Ages:
Between 6 months and 71 months
Trial Updated:
03/22/2023
Locations: 208, Novartis Investigational Site, Austin, Texas +5 locations
Conditions: Influenza Virus
Register for Updates
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05
NCT02255409
Completed
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously Vaccinated in Trial V118_05
Gender:
ALL
Ages:
Between 12 months and 84 months
Trial Updated:
03/06/2023
Locations: Not set, Austin, Texas +3 locations
Conditions: Influenza
Register for Updates
Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age
NCT04526574
Completed
Study of the safety and immunogenicity of 20vPnC and influenza vaccine administered at the same visit or separately
Gender:
ALL
Ages:
65 years and above
Trial Updated:
06/15/2022
Locations: Benchmark Research, Austin, Texas +8 locations
Conditions: Pneumococcal Disease
Register for Updates
INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure
NCT02787044
Completed
INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons. The primary endpoint will be a composite of all-cause mortality or cardiopulmonary hospitalization.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2021
Locations: Austin Heart- Heart Hospital, Austin, Texas +9 locations
Conditions: Heart Failure, Myocardial Infarction
Register for Updates
Safety and Efficacy of SA4Ag Vaccine in Adults Having Elective Open Posterior Spinal Fusion Procedures With Multilevel Instrumentation
NCT02388165
Terminated
The purposes of the clinical trial are to determine whether the SA4Ag vaccine can prevent postoperative Staphylococcus aureus infections in patients who are undergoing elective spinal fusion surgery, and to evaluate the safety of SA4Ag in patients who are undergoing elective spinal surgery.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
12/11/2020
Locations: Dell Seton Medical Center at The University of Texas, Austin, Texas +21 locations
Conditions: Staphylococcal Vaccine
Register for Updates
Influenza Vaccine as a Novel Experimental Model of the Behavioral Immune Response in Depression
NCT03756246
Unknown
The purpose of this study is to determine differences between the immune responses in healthy and depressed people. Participants will receive the influenza vaccine and their responses will be monitored. This study will recruit 15 healthy and 60 depressed participants.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
06/25/2019
Locations: Marisa Toups, Austin, Texas
Conditions: Depression, Healthy
Register for Updates
Evaluation of a Single Vaccination of One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) and a Single Dose Level of a 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) in Healthy Adults Aged 65 to <86 Years
NCT01643941
Completed
This is a Phase 1 and Phase 2 study of a single vaccination with one of three dose levels of a 4-antigen investigational vaccine against Staphylococcus aureus (SA4Ag) and a single dose level of a 3-antigen Staphylococcus aureus vaccine (SA3Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune response elicited by the vaccine in healthy adults aged 65 to \<86 years. In addition, the study aims to assess the effect of the Staph... Read More
Gender:
ALL
Ages:
Between 65 years and 85 years
Trial Updated:
02/28/2019
Locations: Benchmark Research, Austin, Texas
Conditions: Staphylococcal Infections
Register for Updates
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
NCT01364571
Completed
This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune response elicited by the vaccine in healthy adults aged 18 to \<65 years. In addition, the study aims to assess the effect of the SA4Ag vaccine on the presence of the Staphylococcus aureus on the skin and... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
02/28/2019
Locations: Benchmark Research, Austin, Texas +2 locations
Conditions: Staphylococcal Infections
Register for Updates
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
NCT03146403
Terminated
The main purpose of this clinical study is to see if a maintenance dose of GEN-003 reduces the number of days that subjects have a genital herpes recurrence. The second purpose of the study is to evaluate the safety and tolerability of a maintenance dose of GEN-003.
Gender:
ALL
Ages:
All
Trial Updated:
01/29/2019
Locations: Tekton Research, Austin, Texas
Conditions: Genital Herpes, HSV-2 Infection
Register for Updates
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years Old
NCT00224484
Completed
Main goal of this study is to compare the occurrence of serious adverse events (SAEs) between the herpes simplex (gD2-AS04) vaccine group and the Saline control group throughout the study period (up to month 12). The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.
Gender:
FEMALE
Ages:
Between 10 years and 17 years
Trial Updated:
01/03/2019
Locations: GSK Investigational Site, Austin, Texas +5 locations
Conditions: Herpes Simplex
Register for Updates
A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age.
NCT02914275
Completed
This is a study to assess the immune (antibody) response and safety of a Seqirus split virion, inactivated Quadrivalent Influenza Vaccine (Seqirus QIV), in comparison with a US licensed 2016/2017 Quadrivalent Influenza Vaccine (comparator QIV) in a healthy pediatric population 6 months through 59 months of age.
Gender:
ALL
Ages:
Between 6 months and 59 months
Trial Updated:
12/30/2018
Locations: Site 283, Austin, Texas +2 locations
Conditions: Influenza, Human
Register for Updates